

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11856212/publications.pdf>

Version: 2024-02-01

47
papers

7,589
citations

159358

30
h-index

223531

46
g-index

47
all docs

47
docs citations

47
times ranked

4724
citing authors

#	ARTICLE	IF	CITATIONS
1	Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 495-507.	13.9	826
2	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 508-519.	13.9	810
3	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 3230-3236.	6.7	707
4	Tofacitinib versus Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2377-2386.	13.9	630
5	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€fourâ€month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
6	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
7	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
8	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468.	6.3	360
9	Phase IIb doseâ€ranging study of the oral JAK inhibitor tofacitinib (CPâ€690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to diseaseâ€modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339
10	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Diseaseâ€Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	2.9	310
11	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Doubleâ€Blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	2.9	284
12	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 86-94.	0.5	256
13	Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38.	6.7	225
14	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	2.9	213
15	Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib. <i>Arthritis and Rheumatology</i> , 2015, 67, 616-625.	2.9	157
16	Sarilumab and Nonbiologic Diseaseâ€Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2017, 69, 277-290.	2.9	146
17	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
18	Distinguishing rheumatoid arthritis from psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000656.	1.8	90

#	ARTICLE	IF	CITATIONS
19	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	2.9	64
20	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1031-1041.	0.9	62
21	Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2018, 5, 283-291.	1.1	62
22	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1293-1301.	0.5	61
23	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.5	61
24	Risk-Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis. <i>Drugs and Aging</i> , 2007, 24, 239-254.	1.3	56
25	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	1.6	53
26	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. <i>RMD Open</i> , 2016, 2, e000308.	1.8	50
27	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 208.	1.6	48
28	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. <i>Arthritis and Rheumatology</i> , 2021, 73, 2166-2178.	2.9	43
29	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	1.8	36
30	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2017, 3, e000416.	1.8	33
31	Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. <i>RMD Open</i> , 2017, 3, e000491.	1.8	33
32	A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 406-415.	1.6	32
33	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase III/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	1.8	28
34	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1216-1225.	0.9	26
35	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000371.	1.8	26
36	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 139.	1.6	21

#	ARTICLE	IF	CITATIONS
37	A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1525-1533.	0.9	19
38	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018, 45, 177-187.	1.0	18
39	Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000232.	1.8	16
40	Tofacitinib in the treatment of active rheumatoid arthritis in adults. <i>Immunotherapy</i> , 2018, 10, 39-56.	1.0	12
41	Recent issues in JAK inhibitor safety: perspective for the clinician. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 295-307.	1.3	11
42	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214.	1.1	10
43	Etanercept – review of efficacy and safety after five years of clinical use. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 11-23.	0.2	3
44	The efficacy and safety of golimumab in the treatment of arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1131-1143.	1.4	3
45	Safety and efficacy of etanercept in the elderly. <i>Aging Health</i> , 2006, 2, 189-197.	0.3	3
46	Etanercept - review of efficacy and safety after five years of clinical use. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 11-23.	0.2	1
47	Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4369-4372.	1.0	0